Drug Approval | April 10, 2023
Virpax reports on progress of Envelta
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
The facility is over 79,000 square feet and is equipped with packaging lines
The company is addressing these observations
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Subscribe To Our Newsletter & Stay Updated
